BCL2 and acute myeloid leukemia: In contrast, in AML cells, there is heterogeneity in the response to VEN, reflecting the degree to which each cell is dependent on Bcl-2, and this varies between patients depending on the genetic and epigenetic features of each AML patient [4, 5].